Johnson & Johnson JNJ
NYSE JNJ
$266.34 -0.74 (-0.28%)
As of: Sep 10, 2026 · 3:59 PM EDT

Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non-Current Assets came in at $141.3 billion in Q2 2026, up 1.73% year-over-year from $138.9 billion in Q2 2025, and little changed quarter-over-quarter from $141.7 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non-Current Assets across 18 years of filings, most recently posting $141.3 billion for Q2 2026.

  • In Q2 2026, Non-Current Assets rose 1.73% year-over-year to $141.3 billion; the TTM figure through Jun 2026 stood at $564.8 billion (up 10.69% YoY), while the FY2025 annual figure was $143.6 billion, up 15.6% from the prior year.
  • Non-Current Assets came in at $141.3 billion for Q2 2026 at Johnson & Johnson, roughly flat from $141.7 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $143.6 billion in Q4 2025 to a low of $109.9 billion in Q4 2022.
  • Average Non-Current Assets over 5 years is $126.2 billion, with a median of $124.2 billion recorded in 2024.
  • Year-over-year, Non-Current Assets declined 13.64% in 2023 and increased 16.05% in 2026.
  • Over 5 years, Non-Current Assets stood at $109.9 billion in 2022, then increased by 3.8% to $114.1 billion in 2023, then grew by 8.9% to $124.2 billion in 2024, then advanced by 15.6% to $143.6 billion in 2025, then fell by 1.6% to $141.3 billion in 2026.
  • Per Business Quant data, the three most recent Non-Current Assets figures were $141.3 billion in Q2 2026, $141.7 billion in Q1 2026, and $143.6 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Johnson & Johnson 641.14 Bn 620.38 Bn 17.26 Bn 141.29 Bn
2 AbbVie 451.04 Bn 444.47 Bn 12.70 Bn 101.45 Bn
3 Merck 357.43 Bn 350.29 Bn 12.21 Bn 125.00 Mn
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn 94.68 Bn
5 Pfizer 157.52 Bn 145.82 Bn 10.94 Bn 159.77 Bn
6 Sanofi 52.14 Bn 44.76 Bn 10.79 Bn 113.37 Bn
7 Revolution Medicines 42.88 Bn 42.88 Bn - 294.93 Mn
8 Incyte 24.70 Bn 20.16 Bn 1.57 Bn 1.85 Bn
9 United Therapeutics 21.47 Bn 18.80 Bn 683.80 Mn 3.74 Bn
10 Neurocrine Biosciences 15.82 Bn 15.43 Bn 935.80 Mn 3.72 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 141.29 Bn
Mar 29, 2026 141.72 Bn
Dec 28, 2025 143.59 Bn
Sep 28, 2025 138.21 Bn
Jun 29, 2025 138.89 Bn
Mar 30, 2025 122.12 Bn
Dec 29, 2024 124.21 Bn
Sep 29, 2024 125.04 Bn
Jun 30, 2024 123.27 Bn
Mar 31, 2024 114.96 Bn
Dec 31, 2023 114.06 Bn
Oct 1, 2023 112.36 Bn
Jul 2, 2023 131.12 Bn
Apr 2, 2023 131.58 Bn
Jan 1, 2023 132.08 Bn
Oct 2, 2022 109.89 Bn
Jul 3, 2022 113.88 Bn
Apr 3, 2022 117.93 Bn
Jan 2, 2022 121.04 Bn
Oct 3, 2021 119.34 Bn